CU6.AX

Compare

No price history available for this symbol yet.

Fair-value model

Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.

Years of analysisAssumption entries

Analyst estimates unavailable for this ticker.

Held by

portfolios on TandT

Bookmarked by

users

Avg position size

—

of holders' portfolios

13F filers

institutions

Sector

Medical - Specialties

Analyst estimates (consensus)

Year	Est. revenue	Growth	Est. EPS	EPS range	Fwd P/E	# Analysts
2027	$8M	+21.1%	$-0.29	$-0.37–$-0.23	—	3
2028	$63M	+698.3%	$-0.20	$-0.39–$-0.05	—	4
2029	$300M	+373.7%	$0.19	$0.07–$0.31	—	2
2030	$636M	+112.1%	$0.22	$0.18–$0.27	—	1

Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep

Earnings surprises

Beat consensus in 1 of the last 8 reported quarters

Reported	Est. EPS	Actual	Surprise
2026-08-27	$-0.15	$-0.12	+17.6%
2026-02-25	$-0.08	$-0.15	-85.2%
2025-08-28	$-0.08	$-0.12	-51.4%
2025-02-28	$-0.07	$-0.07	-0.7%
2024-08-23	$-0.04	$-0.06	-48.2%
2024-02-29	$-0.05	$-0.07	-31.6%
2023-08-24	$-0.04	$-0.05	-29.6%
2023-02-28	$-0.03

DCF fair valuemodel estimate

Intrinsic value

$0.51

Price

$2.19

Implied downside

-77%

Peer comparison

Symbol	Price	Today	Mkt cap	P/E
CU6.AXClarity Pharmaceuticals Ltd	$2.19	+2.34%	$817M	—
CUV.AXClinuvel Pharmaceuticals Limited	$8.36	+0.60%	$421M	—
DXB.AXDimerix Limited	$0.23	-2.08%	$141M	—
ILA.AXIsland Pharmaceuticals Limited	$0.44	+2.33%	$130M	—
IMM.AXImmutep Limited	$0.04

Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.

www.claritypharmaceuticals.com

Employees: 100
IPO / List date: Aug 25, 2021
HQ: AU

Held by traders on TradeandTell

No one on the platform currently holds CU6.AX.

Super investors & insiders

Institutions holding (13F)

No tracked institution reports a position in CU6.AX as of their last filing.

Insider activity (SEC Form 4)

No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.

Insider activity (SEC Form 4)

Recent trades on TradeandTell

No one on the platform has traded CU6.AX yet.